{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T20:04:02Z","timestamp":1769717042957,"version":"3.49.0"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T00:00:00Z","timestamp":1760572800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002855","name":"Ministry of Science and Technology of the People\u2019s Republic of China","doi-asserted-by":"crossref","award":["2022YFC2407100"],"award-info":[{"award-number":["2022YFC2407100"]}],"id":[{"id":"10.13039\/501100002855","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100002855","name":"Ministry of Science and Technology of the People\u2019s Republic of China","doi-asserted-by":"crossref","award":["2022YFC2407101"],"award-info":[{"award-number":["2022YFC2407101"]}],"id":[{"id":"10.13039\/501100002855","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To compare the survival difference between 2018 International Federation of Gynecology and Obstetrics (FIGO) stage IIB cervical cancer (CC) patients with unilateral parametrial invasion (UL) and bilateral parametrial invasion (BL) disease, and explore the significant role of parametrial invasion (PI) in prognosis prediction.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A total of 506 stage IIB CC patients were identified from the multi-center study, and patients were divided into UL and BL groups according to gynecological and radiological examination. Survival outcomes were estimated and compared between 2 groups before and after propensity scoring matching (PSM). The role of upper 2\/3 vaginal invasion (VI) in impacting survival probability was also assessed. The random forest (RF) model was constructed and validated to select important features related to survival outcomes and predict prognosis for these patients. The SHapley Additive exPlanation (SHAP) was further introduced to provide a better understanding toward the findings from the RF model.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Significant better 5-year overall survival (OS) was observed among patients with UL disease whether before (BL: 61.7% [95% CI: 57.0%-66.4%]; UL: 84.8% [95% CI: 82.4%-87.2%]; HR\u2009=\u20092.83, 95% CI: 1.90-4.20, P\u2009&amp;lt;\u20090.001) or after PSM (BL: 61.3% [95% CI: 56.6%-66.0%]; UL: 81.2% [95% CI: 77.3%-85.1%]; HR\u2009=\u20092.51, 95% CI: 1.56-4.04, P\u2009&amp;lt;\u20090.001). Similar findings could also be observed in terms of progression-free survival (PFS). The presence of VI didn\u2019t significantly impair the survival probability, whether in the UL or BL group (all P\u2009&amp;gt;\u20090.05). RF model was constructed, which possessed decent predictive ability both in the training (area under the receiver operating characteristic curve [AUC]\u2009=\u20090.893; 95% CI: 0.874-0.912) and validation cohort (AUC\u2009=\u20090.879; 95% CI: 0.801-0.957). PI was identified to be the paramount feature in affecting the survival outcomes for stage IIB CC patients through the Beeswarm summary plot and bar chart in SHAP analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our findings demonstrated that 2018 FIGO stage IIB CC patients with BL disease had a worse prognosis than those with UL disease, and PI was the most significant feature in prognosis prediction for these patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/oncolo\/oyaf329","type":"journal-article","created":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T12:28:09Z","timestamp":1760531289000},"source":"Crossref","is-referenced-by-count":0,"title":["Different prognosis for stage IIB cervical cancer patients with unilateral or bilateral parametrial invasion treated with concurrent chemoradiotherapy"],"prefix":"10.1093","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7865-8668","authenticated-orcid":false,"given":"Xi-Lin","family":"Yang","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College , Beijing 10000,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li-Chun","family":"Wei","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital , Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 10000,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian-Li","family":"He","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Xijing Hospital, Air Force Medical University , Xi\u2019an, Shanxi 710000,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tie-Jun","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, General Hospital of Ningxia Medical University , Yinchuan, Ningxia 750000,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Ran","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The Second Affiliated Hospital of Jilin University , Changchun 130041,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li-Juan","family":"Zou","sequence":"additional","affiliation":[{"name":"Department of Oncology, Affiliated Cancer Hospital of Guizhou Medical University , Gui Yang, GuiZhou 550004,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao-Ge","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The Second Affiliated Hospital of Dalian Medical University , Liaoning 116000,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao-Mei","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Affiliated Hospital of Inner Mongolia Medical University , Hohhot, Inner Mongolia 010000,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zi","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Peking University First Hospital 100000 ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong-Gang","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, First Affiliated Hospital of Xian Jiaotong University , Xi\u2019an 719000,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sha","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The First Affiliated Hospital of Zhengzhou University , Zhengzhou 450000,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feng-Ju","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The 940th Hospital of Joint Logistics Support Force of Chinese People\u2019s Liberation Army , Lanzhou 730070,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kun","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy, Gansu Province Cancer Hospital , Lanzhou 730050,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Zhong","sequence":"additional","affiliation":[{"name":"Department of Gynecologic Oncology, Guangxi Medical University Cancer Hospital, 71 Hedi Road, Qingxiu District , Nanning 530000,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guang-Hui","family":"Cheng","sequence":"additional","affiliation":[{"name":"Gynaecological Oncology Radiotherapy (Inpatient Area 1), The Affiliated Cancer Hospital of Xinjiang Medical University , Urumqi 830000,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ya-Li","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, China-Japan Union Hospital of Jilin University , Jilin 130100,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bao-Sheng","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Cangzhou Central Hospital , Cangzhou, Hebei 061000,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun-Fang","family":"Yan","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College , Beijing 10000,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6856-2320","authenticated-orcid":false,"given":"Fu-Quan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College , Beijing 10000,","place":["China"]},{"name":"Department of Radiotherapy, Jilin Province Cancer Hospital , Changchun 130000,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,10,16]]},"reference":[{"key":"2026012903063416200_oyaf329-B1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"2026012903063416200_oyaf329-B2","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1097\/CM9.0000000000002108","article-title":"Cancer statistics in China and United States, 2022: profiles, trends, and determinants","volume":"135","author":"Xia","year":"2022","journal-title":"Chin Med J (Engl)"},{"key":"2026012903063416200_oyaf329-B3","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1007\/s11606-019-05174-5","article-title":"Rising mortality rate of cervical cancer in younger women in urban China","volume":"35","author":"Chen","year":"2020","journal-title":"J Gen Intern Med"},{"key":"2026012903063416200_oyaf329-B4","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1002\/ijgo.15395","article-title":"Cancer of the cervix uteri","volume":"143 Suppl 2","author":"Bhatla","year":"2018","journal-title":"Int J Gynaecol Obstet"},{"key":"2026012903063416200_oyaf329-B5","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/j.ygyno.2020.03.027","article-title":"FIGO 2018 staging criteria for cervical cancer: impact on stage migration and survival","volume":"157","author":"Grigsby","year":"2020","journal-title":"Gynecol Oncol"},{"key":"2026012903063416200_oyaf329-B6","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ygyno.2023.01.023","article-title":"The prognostic value of the presence of pelvic and\/or para-aortic lymph node metastases in cervical cancer patients; the influence of the new FIGO classification (stage IIIC)","volume":"171","author":"van Kol","year":"2023","journal-title":"Gynecol Oncol"},{"key":"2026012903063416200_oyaf329-B7","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.ygyno.2022.02.017","article-title":"Prognostic value of the 2018 FIGO staging system for cervical cancer","volume":"165","author":"Mohamud","year":"2022","journal-title":"Gynecol Oncol"},{"key":"2026012903063416200_oyaf329-B8","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.ygyno.2018.10.026","article-title":"Validation of the 2018 FIGO cervical cancer staging system","volume":"152","author":"Matsuo","year":"2019","journal-title":"Gynecol Oncol"},{"key":"2026012903063416200_oyaf329-B9","author":"Cervical Cancer","year":"2019"},{"key":"2026012903063416200_oyaf329-B10","doi-asserted-by":"crossref","first-page":"295","DOI":"10.21147\/j.issn.1000-9604.2019.02.04","article-title":"Chinese guidelines for diagnosis and treatment of cervical cancer 2018 (English version)","volume":"31","author":"National Health Commission of the People\u2019s Republic of China","year":"2019","journal-title":"Chin J Cancer Res"},{"key":"2026012903063416200_oyaf329-B11","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1016\/j.ejso.2019.02.019","article-title":"Predictors for pathological parametrial invasion in clinical stage IIB cervical cancer","volume":"45","author":"Matsuo","year":"2019","journal-title":"Eur J Surg Oncol"},{"key":"2026012903063416200_oyaf329-B12","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1186\/s12905-023-02427-8","article-title":"Stage IIB-IVA cervix carcinoma in elderly patients treated with radiation therapy: a longitudinal cohort study by propensity score matching analysis","volume":"23","author":"Shou","year":"2023","journal-title":"BMC Womens Health"},{"key":"2026012903063416200_oyaf329-B13","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1186\/s13014-022-02115-1","article-title":"Outcomes and prognostic factors in patients with locally advanced cervical cancer treated with concurrent chemoradiotherapy","volume":"17","author":"Liu","year":"2022","journal-title":"Radiat Oncol"},{"key":"2026012903063416200_oyaf329-B14","doi-asserted-by":"publisher","first-page":"2939162","DOI":"10.1155\/2021\/2939162","article-title":"Neutrophil-to-lymphocyte ratio (NLR) and monocyte-to-lymphocyte ratio (MLR) predict clinical outcome in patients with stage IIB cervical cancer","volume":"2021","author":"Li","year":"2021","journal-title":"J Oncol"},{"key":"2026012903063416200_oyaf329-B15","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1002\/1097-0142(19920115)69:2<482::AID-CNCR2820690235>3.0.CO;2-8","article-title":"A reappraisal of the international federation of gynecology and obstetrics staging system for cervical cancer. A study of patterns of care","volume":"69","author":"Lanciano","year":"1992","journal-title":"Cancer"},{"key":"2026012903063416200_oyaf329-B16","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","article-title":"The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"370","author":"von Elm","year":"2007","journal-title":"Lancet"},{"key":"2026012903063416200_oyaf329-B17","doi-asserted-by":"publisher","first-page":"14","DOI":"10.6004\/jnccn.2008.0003","article-title":"Cervical cancer","volume":"6","author":"Greer","year":"2008","journal-title":"J Natl Compr Canc Netw"},{"key":"2026012903063416200_oyaf329-B18","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1002\/sim.5984","article-title":"The use of propensity score methods with survival or time-to-event outcomes: reporting measures of effect similar to those used in randomized experiments","volume":"33","author":"Austin","year":"2014","journal-title":"Stat Med"},{"key":"2026012903063416200_oyaf329-B19","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/s42256-019-0138-9","article-title":"From local explanations to global understanding with explainable AI for trees","volume":"2","author":"Lundberg","year":"2020","journal-title":"Nat Mach Intell"},{"key":"2026012903063416200_oyaf329-B20","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.1021\/ci034160g","article-title":"Random forest: a classification and regression tool for compound classification and QSAR modeling","volume":"43","author":"Svetnik","year":"2003","journal-title":"J Chem Inf Comput Sci"},{"key":"2026012903063416200_oyaf329-B21","doi-asserted-by":"publisher","first-page":"e2300478","DOI":"10.1200\/GO.23.00478","article-title":"Longitudinal costs of image-guided intensity-modulated radiation therapy versus three-dimensional conformal radiation: lessons from phase III PARCER trial for shaping resource-stratified guidelines in low- and middle-income countries","volume":"10","author":"Hande","year":"2024","journal-title":"JCO Glob Oncol."},{"key":"2026012903063416200_oyaf329-B22","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1186\/s13014-018-1126-7","article-title":"Intensity-modulated radiation therapy for definitive treatment of cervical cancer: a meta-analysis","volume":"13","author":"Lin","year":"2018","journal-title":"Radiat Oncol"},{"key":"2026012903063416200_oyaf329-B23","doi-asserted-by":"publisher","first-page":"e14","DOI":"10.3802\/jgo.2022.33.e14","article-title":"Comparison of treatment outcomes of surgery and radiotherapy, including concurrent chemoradiotherapy for stage Ib2-IIb cervical adenocarcinoma patients: a retrospective study","volume":"33","author":"Kondo","year":"2022","journal-title":"J Gynecol Oncol"},{"key":"2026012903063416200_oyaf329-B24","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/538020a","article-title":"Can we open the black box of AI?","volume":"538","author":"Castelvecchi","year":"2016","journal-title":"Nature"},{"key":"2026012903063416200_oyaf329-B25","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.ygyno.2021.04.005","article-title":"Different prognosis of stage IIIB cervical cancer patients with lower third of vaginal invasion and those without","volume":"162","author":"Fang","year":"2021","journal-title":"Gynecol Oncol"},{"key":"2026012903063416200_oyaf329-B26","doi-asserted-by":"publisher","first-page":"e82","DOI":"10.3802\/jgo.2019.30.e82","article-title":"A randomized controlled trial comparing concurrent chemoradiation versus concurrent chemoradiation followed by adjuvant chemotherapy in locally advanced cervical cancer patients: ACTLACC trial","volume":"30","author":"Tangjitgamol","year":"2019","journal-title":"J Gynecol Oncol"},{"key":"2026012903063416200_oyaf329-B27","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/S1470-2045(23)00147-X","article-title":"Adjuvant chemotherapy following chemoradiotherapy as primary treatment for locally advanced cervical cancer versus chemoradiotherapy alone (OUTBACK): an international, open-label, randomised, phase 3 trial","volume":"24","author":"Mileshkin","year":"2023","journal-title":"Lancet Oncol"},{"key":"2026012903063416200_oyaf329-B28","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1186\/s12957-022-02859-w","article-title":"The comparative study for survival outcome of locally advanced cervical cancer treated by neoadjuvant arterial interventional chemotherapy or intravenous chemotherapy followed by surgery or concurrent chemoradiation","volume":"20","author":"Sun","year":"2022","journal-title":"World J Surg Oncol"},{"key":"2026012903063416200_oyaf329-B29","doi-asserted-by":"crossref","first-page":"e82","DOI":"10.3802\/jgo.2025.36.e82","article-title":"Adjuvant chemotherapy after radical hysterectomy yields comparable outcomes to chemoradiation for stage IB2-IIB and IIIC1-2 cervical cancer: a single-center retrospective study","volume":"36","author":"Chikazawa","year":"2025","journal-title":"J Gynecol Oncol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyaf329\/64717752\/oyaf329.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/11\/oyaf329\/64717752\/oyaf329.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/11\/oyaf329\/64717752\/oyaf329.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T08:06:39Z","timestamp":1769673999000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyaf329\/8287639"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,16]]},"references-count":29,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11,11]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyaf329","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,11]]},"published":{"date-parts":[[2025,10,16]]},"article-number":"oyaf329"}}